Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

[1]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[2]  E. Tolosa,et al.  The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases , 2014, Movement disorders : official journal of the Movement Disorder Society.

[3]  Clifford R Jack,et al.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial , 2014, The Lancet Neurology.

[4]  E. Tolosa,et al.  A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.

[5]  A. Boxer,et al.  Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes , 2014, Seminars in Neurology.

[6]  T. Ferman,et al.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. , 2013, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[7]  C. Jack,et al.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. , 2012, Parkinsonism & related disorders.

[8]  Albert C. Ludolph,et al.  Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE , 2011, PloS one.

[9]  Y. Agid,et al.  Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. , 2010, Brain : a journal of neurology.

[10]  M. Jahanshahi,et al.  A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy , 2010, Movement disorders : official journal of the Movement Disorder Society.

[11]  David R Williams,et al.  Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges , 2009, The Lancet Neurology.

[12]  Y. Agid,et al.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study , 2008, Brain : a journal of neurology.

[13]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[14]  T. Révész,et al.  Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[15]  Ulrike Groemping,et al.  Relative Importance for Linear Regression in R: The Package relaimpo , 2006 .

[16]  D. Burn,et al.  Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[17]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[18]  Jeffrey L. Cummings,et al.  Neuropsychiatric aspects of progressive supranuclear palsy , 1996, Neurology.

[19]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[20]  A. Siderowf.  Schwab and England Activities of Daily Living Scale , 2010 .

[21]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[22]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .